Company Overview
| Stock Name | Alphamab-B |
|---|---|
| Stock Code | 09966 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 中國領先的臨床階段生物製藥公司,在雙特異性及蛋白質工程方面擁有全面整合的專有生物製劑平台,開發腫瘤候選藥物。 |
| Listing Date | 2019-12-12 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 江蘇省蘇州市蘇州工業園區星湖街218號C23樓401和501室 |
| Business Address (Hong Kong) | 銅鑼灣希慎道33號利園一期19樓1901室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | alphamabonc.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 10.20 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2019-12-02 to 2019-12-05 |
| Global Offering Shares | 179,403,000 shares |
| HK Public Offer Shares (Initial) | 17,942,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 161,461,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 897,011,575 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 49.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,829,910,600 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 10,200 |
| 2 lots | 2,000 | HK$ 20,400 |
| 3 lots | 3,000 | HK$ 30,600 |
| 4 lots | 4,000 | HK$ 40,800 |
| 5 lots | 5,000 | HK$ 51,000 |
| 6 lots | 6,000 | HK$ 61,200 |
| 7 lots | 7,000 | HK$ 71,400 |
| 8 lots | 8,000 | HK$ 81,600 |
| 9 lots | 9,000 | HK$ 91,800 |
| 10 lots | 10,000 | HK$ 102,000 |
| 15 lots | 15,000 | HK$ 153,000 |
| 20 lots | 20,000 | HK$ 204,000 |
| 25 lots | 25,000 | HK$ 255,000 |
| 30 lots | 30,000 | HK$ 306,000 |
| 35 lots | 35,000 | HK$ 357,000 |
| 40 lots | 40,000 | HK$ 408,000 |
| 45 lots | 45,000 | HK$ 459,000 |
| 50 lots | 50,000 | HK$ 510,000 |
| 60 lots | 60,000 | HK$ 612,000 |
| 70 lots | 70,000 | HK$ 714,000 |
| 80 lots | 80,000 | HK$ 816,000 |
| 90 lots | 90,000 | HK$ 918,000 |
| 100 lots | 100,000 | HK$ 1,020,000 |
| 200 lots | 200,000 | HK$ 2,040,000 |
| 300 lots | 300,000 | HK$ 3,060,000 |
| 400 lots | 400,000 | HK$ 4,080,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 500 lots | 500,000 | HK$ 5,100,000 |
| 600 lots | 600,000 | HK$ 6,120,000 |
| 700 lots | 700,000 | HK$ 7,140,000 |
| 800 lots | 800,000 | HK$ 8,160,000 |
| 900 lots | 900,000 | HK$ 9,180,000 |
| 1,000 lots | 1,000,000 | HK$ 10,200,000 |
| 2,000 lots | 2,000,000 | HK$ 20,400,000 |
| 3,000 lots | 3,000,000 | HK$ 30,600,000 |
| 4,000 lots | 4,000,000 | HK$ 40,800,000 |
| 5,000 lots | 5,000,000 | HK$ 51,000,000 |
| 6,000 lots | 6,000,000 | HK$ 61,200,000 |
| 7,000 lots | 7,000,000 | HK$ 71,400,000 |
| 8,000 lots | 8,000,000 | HK$ 81,600,000 |
| 8,971 lots | 8,971,000 | HK$ 91,504,200 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 7.73B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +21% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 亏损人民币202.6百万元 |
| Period-End Cash Balance | 人民币633.7百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 |
|---|---|---|
| Other income and gains, net | 1,428 | -9,050 |
| Administrative expenses | -13,025 | -25,857 |
| Operating profit | -64,818 | -201,126 |
| Net finance costs | -8 | -1,507 |
| Profit before tax | -64,826 | -202,633 |
| Income tax expense | 0 | 0 |
| Profit for the year | -64,826 | -202,633 |
| Profit attributable to owners | -33,061 | -149,843 |
Balance Sheet
| Item | 2017 | 2018 | 2019-06 |
|---|---|---|---|
| Cash and cash equivalents | 57 | 633,712 | |
| Inventories | 3,486 | 7,068 | |
| Total current assets | 11,215 | 656,103 | |
| Total assets | 46,577 | 826,893 | |
| Total current liabilities | 10,266 | 82,800 | |
| Total liabilities | 20,266 | 1,093,921 | |
| Total equity | 26,311 | -267,028 | |
| Equity attributable to owners | 13,419 | -267,028 | |
| Interest-bearing borrowings | 0 | 100,000 | 150,000 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019-06 |
|---|---|---|---|
| Net cash from operating activities | -65,161 | -93,874 | |
| Net cash from investing activities | 2,305 | -72,110 | |
| Net cash from financing activities | 2,000 | 798,800 | |
| Net increase in cash | 12 | 642,353 | |
| Depreciation of PP&E | 101 | 266 | 344 |
| Depreciation of right-of-use assets | 413 | 6,296 | 4,685 |
| Purchase of PP&E | -34,000 | -48,900 | -1,680 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 13.5 |
|---|---|
| First Day Open | HK$ 13.0 |
| First Day Change | 32.35% |
| First Day Volume | 115582000.0 |
| First Day Turnover | 1499270000.0 |
| Use of Proceeds | 1、約50%(或854.6百萬港元)將用于我們的核心產品KN046的研發及商業化;
2、約20%(或341.8百萬港元)將用于KN026的研發及商業化;
3、約5%(或85.5百萬港元)將用于KN019的研發;
4、約15%(或256.4百萬港元)將用于我們于蘇州的新制造及研發設施的建設;
5、約10%(或170.9百萬港元)將用于我們的早期管線及作營運資金及一般公司用途。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (3)
Joint Bookrunners (7)
Joint Lead Managers (7)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Lake Bleu Prime Healthcare Master Fund Limited | 103,193,400 HKD | — | 5.60% | — | 6 months | 2020-06-12 |
| 2 | Matthews Asia Funds | 192,616,800 HKD | — | 10.50% | — | 6 months | 2020-06-12 |
| 3 | OrbiMed Funds | 137,608,200 HKD | — | 7.50% | — | 6 months | 2020-06-12 |
| 4 | 景林资产管理有限公司 | 137,577,600 HKD | — | 7.50% | — | 6 months | 2020-06-12 |
| 5 | 绿叶制药集团有限公司 | 34,394,400 HKD | — | 1.90% | — | 6 months | 2020-06-12 |
| 6 | 摩根士丹利亚洲有限公司 | 103,183,200 HKD | — | 5.60% | — | 6 months | 2020-06-12 |
| 7 | 泰康人寿保险有限责任公司 | 206,376,600 HKD | — | 11.30% | — | 6 months | 2020-06-12 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 徐霆 | — |
| Company Secretary | 帥琪、黃綺汶 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 徐博士(透過Rubymab)緊隨全球發售完成後持股約36.62%,為控股股東;張喜田先生(透過Sky Diamond)9.56%;薛傳校先生(透過Pearlmed)9.56%;PAG Growth 5.54%;Advantech II 5.51%。 |
|---|




